PCSK1 and Bardet-Biedl syndrome: Setmelanotide has also been approved for the treatment of obesity and hunger due to genetic disorders such as Bardet-Biedl syndrome, pro-opiomelanocortin (POMC) loss-of-function, including proprotein convertase subtilisin/kexin type 1 (PCSK1), and LEPR deficiency [23].